Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Filings indexed 481 across all filing types
Latest filing 2021-01-06 Director's Dealing
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-01-05 English
FORM 3 SUBMISSION
Director's Dealing
2021-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-18 English
FORM 4 SUBMISSION
Director's Dealing
2020-12-18 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 9, 2020, reporting the appointment of a new Chief Financial Officer and the resignation of the interim CFO. It details the executive employment agreement, compensation, and severance terms. The content focuses on management changes and related agreements. There are no financial statements or quarterly/yearly financial results presented. The document is not an earnings release, annual report, or interim report. It is a regulatory filing specifically announcing a change in senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (8968 characters) supports it being a full filing rather than a brief announcement or certification.
2020-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.